Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

85.60CHF
4:03am EDT
Change (% chg)

CHF1.52 (+1.81%)
Prev Close
CHF84.08
Open
CHF84.44
Day's High
CHF85.70
Day's Low
CHF84.40
Volume
1,061,815
Avg. Vol
4,393,116
52-wk High
CHF88.30
52-wk Low
CHF71.84

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.15
Market Cap(Mil.): CHF214,753.30
Shares Outstanding(Mil.): 2,550.62
Dividend: 2.80
Yield (%): 3.33

Financials

  NOVN.S Industry Sector
P/E (TTM): 14.46 29.75 32.14
EPS (TTM): 5.82 -- --
ROI: 12.45 13.18 12.83
ROE: 18.79 15.14 14.95

BRIEF-Sandoz Launches Biosimilar Version Of Abbvie's Humira In UK

* NOVARTIS UNIT SANDOZ LAUNCHES HYRIMOZ, ITS BIOSIMILAR VERSION OF ABBVIE'S HUMIRA, IN UK AS OF OCT 16; OTHER EUROPEAN MARKETS TO FOLLOW -SPOKESMAN Further company coverage: (Reporting by UK bureau)

Oct 16 2018

BRIEF-Novartis says 5-year data reinforce cosentyx leadership in spondyloarthritis

* NOVARTIS 5-YEAR DATA IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS REINFORCES COSENTYX® LEADERSHIP IN SPONDYLOARTHRITIS Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Oct 16 2018

Abbvie settles Humira patent disputes with Novartis unit

Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira.

Oct 12 2018

Abbvie settles Humira patent disputes with Novartis unit

Oct 11 Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira.

Oct 11 2018

BRIEF-Novartis Announces Data From Trial To Show Superior Efficacy Of Gilenya Over Copaxone In Patients With Relapsing Remitting Multiple Sclerosis

* NOVARTIS ANNOUNCES NEW DATA FROM THE FIRST DIRECT HEAD-TO-HEAD TRIAL TO DEMONSTRATE SUPERIOR EFFICACY OF GILENYA® OVER COPAXONE® IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS

Oct 10 2018

BRIEF-Novartis seeks U.S., EU regulatory approval for MS drug Siponimod

* NOVARTIS ANNOUNCES FDA AND EMA FILING ACCEPTANCE OF SIPONIMOD, THE FIRST AND ONLY DRUG SHOWN TO MEANINGFULLY DELAY DISABILITY PROGRESSION IN TYPICAL SPMS PATIENTS

Oct 08 2018

BRIEF-Novartis licenses three anti-infective programnes to Boston Pharmaceuticals

* NOVARTIS LICENSES THREE NOVEL ANTI-INFECTIVE PROGRAMS TO BOSTON PHARMACEUTICALS

Oct 03 2018

Rare manufacturing glitch raises concern over CAR-T therapies: study

CHICAGO A single leukemia cell inadvertently got mixed in with a batch of a patient's immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported on Monday.

Oct 01 2018

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

Sep 27 2018

UPDATE 1-Novartis strikes deal with Chinese firm to make Kymriah

ZURICH, Sept 27 Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country. Local regulations require that Novartis manufactures Kymriah in China if it wants to treat the country's patients with the drug.

Sep 27 2018

Earnings vs. Estimates